Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Imfinzi | durvalumab | Extensive-stage small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | limited-stage small cell lung cancer (LS-SCLC) | Pending | |||
Imfinzi | durvalumab | resectable non-small cell lung cancer (NSCLC) | Active | |||
Imfinzi | durvalumab, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair deficient (dMMR) | Received | |||
Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi, Imjudo | durvalumab, tremelimumab | Metastatic non-small cell lung cancer (NSCLC) | Received | |||
Imfinzi, Lynparza | durvalumab, olaparib, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair proficient (pMMR) | Received | |||
Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete |